{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:39:08Z","timestamp":1785213548731,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2021YFC2501700"],"award-info":[{"award-number":["2021YFC2501700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070908"],"award-info":[{"award-number":["82070908"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370894"],"award-info":[{"award-number":["82370894"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-051"],"award-info":[{"award-number":["2021-I2M-1-051"]}]},{"name":"National High-Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-014"],"award-info":[{"award-number":["2022-PUMCH-B-014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>We aim to detect serum DKK1 level of pediatric patients with OI and to analyze its relationship with the genotype and phenotype of OI patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cohort of pediatric OI patients and age-matched healthy children were enrolled. Serum levels of DKK1 and bone turnover biomarkers were measured by enzyme-linked immunosorbent assay. Bone mineral density (BMD) was measured by Dual-energy X-ray absorptiometry. Pathogenic mutations of OI were detected by next-generation sequencing and confirmed by Sanger sequencing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 62 OI children with mean age of 9.50 (4.86, 12.00) years and 29 healthy children were included in this study. The serum DKK1 concentration in OI children was significantly higher than that in healthy children [5.20 (4.54, 6.32) and 4.08 (3.59, 4.92) ng\/mL, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001]. The serum DKK1 concentration in OI children was negatively correlated with height (r\u2009=\u2009\u2212\u00a00.282), height Z score (r\u2009=\u2009\u2212\u00a00.292), ALP concentration (r\u2009=\u2009\u2212\u00a00.304), lumbar BMD (r\u2009=\u2009\u2212\u00a00.276), BMD Z score of the lumbar spine and femoral neck (r\u2009=\u2009\u2212\u00a00.32; r\u2009=\u2009\u2212\u00a00.27) (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). No significant difference in serum DKK1 concentration was found between OI patients with and without vertebral compression fractures. In patients with spinal deformity (22\/62), serum DKK1 concentration was positively correlated with SDI (r\u2009=\u20090.480, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). No significant correlation was observed between serum DKK1 concentration and the annual incidence of peripheral fractures, genotype and types of collagen changes in OI children.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The serum DKK1 level was not only significantly elevated in OI children, but also closely correlated to their skeletal phenotype, suggesting that DKK1 may become a new biomarker and a potential therapeutic target of OI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-024-02380-9","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T19:01:53Z","timestamp":1715713313000},"page":"2785-2795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Correlation of serum DKK1 level with skeletal phenotype in children with osteogenesis imperfecta"],"prefix":"10.1007","volume":"47","author":[{"given":"Y.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7270-4902","authenticated-orcid":false,"given":"M.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"2380_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.metabol.2017.06.001","volume":"80","author":"S Tournis","year":"2018","unstructured":"Tournis S, Dede AD (2018) Osteogenesis imperfect\u2014a clinical update. Metab Clin Exp 80:27\u201337","journal-title":"Metab Clin Exp"},{"key":"2380_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02179-0","author":"MM Formosa","year":"2023","unstructured":"Formosa MM, Christou MA, M\u00e4kitie O (2023) Bone fragility and osteoporosis in children and young adults. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-023-02179-0","journal-title":"J Endocrinol Invest"},{"key":"2380_CR3","doi-asserted-by":"publisher","first-page":"9416","DOI":"10.3390\/ijms24119416","volume":"24","author":"M Gnoli","year":"2023","unstructured":"Gnoli M, Brizola E, Tremosini M, Di Cecco A, Sangiorgi L (2023) Vitamin d and bone fragility in individuals with osteogenesis imperfecta: a scoping review. Int J Mol Sci 24:9416","journal-title":"Int J Mol Sci"},{"key":"2380_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.matbio.2023.06.004","volume":"121","author":"M Jovanovic","year":"2023","unstructured":"Jovanovic M, Mitra A, Besio R, Contento BM, Wong KW, Derkyi A et al (2023) Absence of tric-b from type xiv osteogenesis imperfecta osteoblasts alters cell adhesion and mitochondrial function\u2014a multi-omics study. Matrix Biol J Int Soc Matrix Biol 121:127\u2013148","journal-title":"Matrix Biol J Int Soc Matrix Biol"},{"key":"2380_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.matbio.2023.06.003","volume":"121","author":"V Daponte","year":"2023","unstructured":"Daponte V, Tonelli F, Masiero C, Syx D, Exbrayat-H\u00e9ritier C, Biggiogera M et al (2023) Cell differentiation and matrix organization are differentially affected during bone formation in osteogenesis imperfecta zebrafish models with different genetic defects impacting collagen type i structure. Matrix biol J Int Soc Matrix Biol 121:105\u2013126","journal-title":"Matrix biol J Int Soc Matrix Biol"},{"key":"2380_CR6","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1210\/clinem\/dgac752","volume":"108","author":"J Hu","year":"2023","unstructured":"Hu J, Lin X, Gao P, Zhang Q, Zhou B, Wang O et al (2023) Genotypic and phenotypic spectrum and pathogenesis of wnt1 variants in a large cohort of patients with oi\/osteoporosis. J Clin Endocrinol Metab 108:1776\u20131786","journal-title":"J Clin Endocrinol Metab"},{"key":"2380_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X et al (2022) Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther 7:3","journal-title":"Signal Transduct Target Ther"},{"key":"2380_CR8","doi-asserted-by":"publisher","first-page":"12441","DOI":"10.3390\/ijms241512441","volume":"24","author":"SK Wong","year":"2023","unstructured":"Wong SK, Mohamad NV, Jayusman PA, Ibrahim N (2023) A review on the crosstalk between insulin and wnt\/\u03b2-catenin signalling for bone health. Int J Mol Sci 24:12441","journal-title":"Int J Mol Sci"},{"key":"2380_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00223-022-01020-9","volume":"112","author":"AS Dincel","year":"2023","unstructured":"Dincel AS, J\u00f8rgensen NR (2023) New emerging biomarkers for bone disease: sclerostin and dickkopf-1 (dkk1). Calcif Tissue Int 112:243\u2013257","journal-title":"Calcif Tissue Int"},{"key":"2380_CR10","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","volume":"382","author":"N Bishop","year":"2013","unstructured":"Bishop N, Adami S, Ahmed SF, Ant\u00f3n J, Arundel P, Burren CP et al (2013) Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet 382:1424\u20131432","journal-title":"Lancet"},{"key":"2380_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.bone.2019.06.011","volume":"127","author":"LJ Li","year":"2019","unstructured":"Li LJ, Zheng WB, Zhao DC, Yu W, Wang O, Jiang Y et al (2019) Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta. Bone 127:164\u2013171","journal-title":"Bone"},{"key":"2380_CR12","first-page":"487","volume":"47","author":"H Li","year":"2009","unstructured":"Li H, Ji CY, Zong XN, Zhang YQ (2009) height and weight standardized growth charts for chinese children and adolescents aged 0 to 18 years. Zhonghua er ke za zhi Chin J Pediatr 47:487\u2013492","journal-title":"Zhonghua er ke za zhi Chin J Pediatr"},{"key":"2380_CR13","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"2380_CR14","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00198-008-0832-7","volume":"20","author":"S Kerkeni","year":"2009","unstructured":"Kerkeni S, Kolta S, Fechtenbaum J, Roux C (2009) Spinal deformity index (sdi) is a good predictor of incident vertebral fractures. Osteoporos Int 20:1547\u20131552","journal-title":"Osteoporos Int"},{"key":"2380_CR15","first-page":"19","volume":"101","author":"AL Kuznia","year":"2020","unstructured":"Kuznia AL, Hernandez AK, Lee LU (2020) Adolescent idiopathic scoliosis: common questions and answers. Am Fam Physician 101:19\u201323","journal-title":"Am Fam Physician"},{"key":"2380_CR16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.bone.2010.12.013","volume":"48","author":"AV Khadilkar","year":"2011","unstructured":"Khadilkar AV, Sanwalka NJ, Chiplonkar SA, Khadilkar VV, Mughal MZ (2011) Normative data and percentile curves for dual energy x-ray absorptiometry in healthy indian girls and boys aged 5\u201317 years. Bone 48:810\u2013819","journal-title":"Bone"},{"key":"2380_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082098","volume":"8","author":"H Xu","year":"2013","unstructured":"Xu H, Zhao Z, Wang H, Ding M, Zhou A, Wang X et al (2013) Bone mineral density of the spine in 11,898 chinese infants and young children: a cross-sectional study. PLoS ONE 8:e82098","journal-title":"PLoS ONE"},{"key":"2380_CR18","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1530\/EJE-20-0299","volume":"183","author":"R Marom","year":"2020","unstructured":"Marom R, Rabenhorst BM, Morello R (2020) Osteogenesis imperfecta: an update on clinical features and therapies. Eur J Endocrinol 183:R95-r106","journal-title":"Eur J Endocrinol"},{"key":"2380_CR19","doi-asserted-by":"publisher","first-page":"115835","DOI":"10.1016\/j.bone.2020.115835","volume":"145","author":"MP Whyte","year":"2021","unstructured":"Whyte MP, Aronson J, McAlister WH, Weinstein RS, Wenkert D, Clements KL et al (2021) Coalescing expansile skeletal disease: Delineation of an extraordinary osteopathy involving the ifitm5 mutation of osteogenesis imperfecta type v. Bone 145:115835","journal-title":"Bone"},{"key":"2380_CR20","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s00198-017-4143-8","volume":"28","author":"Y Liu","year":"2017","unstructured":"Liu Y, Asan MD, Lv F, Xu X, Wang J et al (2017) Gene mutation spectrum and genotype-phenotype correlation in a cohort of chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing. Osteoporos Int 28:2985\u20132995","journal-title":"Osteoporos Int"},{"key":"2380_CR21","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00439-021-02302-2","volume":"140","author":"L Claeys","year":"2021","unstructured":"Claeys L, Storoni S, Eekhoff M, Elting M, Wisse L, Pals G et al (2021) Collagen transport and related pathways in osteogenesis imperfecta. Hum Genet 140:1121\u20131141","journal-title":"Hum Genet"},{"key":"2380_CR22","first-page":"405","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the american college of medical genetics and genomics and the association for molecular pathology. Genet Med Off J Am Coll Med Genet 17:405\u2013424","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"2380_CR23","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","volume":"363","author":"F Rauch","year":"2004","unstructured":"Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363:1377\u20131385","journal-title":"Lancet"},{"key":"2380_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.847387","volume":"13","author":"H Jiang","year":"2022","unstructured":"Jiang H, Zhang Z, Yu Y, Chu HY, Yu S, Yao S et al (2022) Drug discovery of dkk1 inhibitors. Front Pharmacol 13:847387","journal-title":"Front Pharmacol"},{"key":"2380_CR25","first-page":"1438","volume":"13","author":"SJ Kuo","year":"2023","unstructured":"Kuo SJ, Chen CL, Chen SH, Ko JY (2023) Changes in serum bone metabolism markers after living donor liver transplantation (ldlt) and their association with fracture occurrences. Life (Basel, Switzerland) 13:1438","journal-title":"Life (Basel, Switzerland)"},{"key":"2380_CR26","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.3390\/jcm12134440","volume":"12","author":"V Gerov","year":"2023","unstructured":"Gerov V, Gerova D, Micheva I, Nikolova M, Mihaylova G, Galunska B (2023) Dynamics of bone disease biomarkers dickkopf-1 and sclerostin in patients with multiple myeloma. J Clin Med 12:4440","journal-title":"J Clin Med"},{"key":"2380_CR27","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.3390\/ijms23063112","volume":"23","author":"YC Gau","year":"2022","unstructured":"Gau YC, Yeh TJ, Hsu CM, Hsiao SY, Hsiao HH (2022) Pathogenesis and treatment of myeloma-related bone disease. Int J Mol Sci 23:3112","journal-title":"Int J Mol Sci"},{"key":"2380_CR28","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ncb3613","volume":"19","author":"X Zhuang","year":"2017","unstructured":"Zhuang X, Zhang H, Li X, Li X, Cong M, Peng F et al (2017) Differential effects on lung and bone metastasis of breast cancer by wnt signalling inhibitor dkk1. Nat Cell Biol 19:1274\u20131285","journal-title":"Nat Cell Biol"},{"key":"2380_CR29","first-page":"4812","volume":"13","author":"X Ma","year":"2021","unstructured":"Ma X, Zhu X, He X, Yi X, Jin A (2021) The wnt pathway regulator expression levels and their relationship to bone metabolism in thoracolumbar osteoporotic vertebral compression fracture patients. Am J Transl Res 13:4812\u20134818","journal-title":"Am J Transl Res"},{"key":"2380_CR30","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s00198-016-3501-2","volume":"27","author":"G Brunetti","year":"2016","unstructured":"Brunetti G, Papadia F, Tummolo A, Fischetto R, Nicastro F, Piacente L et al (2016) Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: The role of dkk1, rankl, and tnf-\u03b1. Osteoporos Int 27:2355\u20132365","journal-title":"Osteoporos Int"},{"key":"2380_CR31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/biomedicines11020465","volume":"11","author":"JY Ko","year":"2023","unstructured":"Ko JY, Wang FS, Chen SH, Kuo SJ (2023) Micro ribonucleic acid-29a (mir-29a) antagonist normalizes bone metabolism in osteogenesis imperfecta (oi) mice model. Biomedicines 11:465","journal-title":"Biomedicines"},{"key":"2380_CR32","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83142","author":"M Zaidi","year":"2023","unstructured":"Zaidi M, Kim SM, Mathew M, Korkmaz F, Sultana F, Miyashita S et al (2023) Bone circuitry and interorgan skeletal crosstalk. Elife. https:\/\/doi.org\/10.7554\/eLife.83142","journal-title":"Elife"},{"key":"2380_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12519-018-0198-7","volume":"15","author":"G Brunetti","year":"2019","unstructured":"Brunetti G, D\u2019Amato G, Chiarito M, Tullo A, Colaianni G, Colucci S et al (2019) An update on the role of rankl-rank\/osteoprotegerin and wnt-\u00df-catenin signaling pathways in pediatric diseases. World J Pediatr WJP 15:4\u201311","journal-title":"World J Pediatr WJP"},{"key":"2380_CR34","doi-asserted-by":"publisher","first-page":"116087","DOI":"10.1016\/j.bone.2021.116087","volume":"153","author":"RB Choi","year":"2021","unstructured":"Choi RB, Robling AG (2021) The wnt pathway: an important control mechanism in bone\u2019s response to mechanical loading. Bone 153:116087","journal-title":"Bone"},{"key":"2380_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/ahg.12399","volume":"84","author":"B Zhang","year":"2020","unstructured":"Zhang B, Li R, Wang W, Zhou X, Luo B, Zhu Z et al (2020) The role of wnt1 mutant variant (wnt1(c.677c>t) ) in osteogenesis imperfecta. Ann Hum Genet 84:447\u2013455","journal-title":"Ann Hum Genet"},{"key":"2380_CR36","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"2380_CR37","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"2380_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.aace.2023.10.002","volume":"9","author":"A Dattagupta","year":"2023","unstructured":"Dattagupta A, Petak S (2023) Osteoporosis improved by romosozumab therapy in a patient with type i osteogenesis imperfecta. AACE clinical case reports 9:209\u2013212","journal-title":"AACE clinical case reports"},{"key":"2380_CR39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/mrcr\/rxab018","volume":"6","author":"M Uehara","year":"2022","unstructured":"Uehara M, Nakamura Y, Nakano M, Miyazaki A, Suzuki T, Takahashi J (2022) Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: a case report. Modern rheumatology case reports 6:128\u2013133","journal-title":"Modern rheumatology case reports"},{"key":"2380_CR40","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/jbmr.3143","volume":"32","author":"FH Glorieux","year":"2017","unstructured":"Glorieux FH, Devogelaer JP, Durigova M, Goemaere S, Hemsley S, Jakob F et al (2017) Bps804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial. J Bone Miner Res 32:1496\u20131504","journal-title":"J Bone Miner Res"},{"key":"2380_CR41","unstructured":"Lewiecki EM (2023) Evaluating setrusumab for the treatment of osteogenesis imperfecta: phase 2 data from the phase 2\/3 ORBIT study. J Bone Miner Res 38(2)"},{"key":"2380_CR42","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.7150\/thno.63177","volume":"12","author":"L Wang","year":"2022","unstructured":"Wang L, Yu Y, Ni S, Li D, Liu J, Xie D et al (2022) Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice. Theranostics 12:5645\u20135674","journal-title":"Theranostics"},{"key":"2380_CR43","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00223-019-00655-5","volume":"106","author":"M Cardinal","year":"2020","unstructured":"Cardinal M, Dessain A, Roels T, Lafont S, Ominsky MS, Devogelaer JP et al (2020) Sclerostin-antibody treatment decreases fracture rates in axial skeleton and improves the skeletal phenotype in growing oim\/oim mice. Calcif Tissue Int 106:494\u2013508","journal-title":"Calcif Tissue Int"},{"key":"2380_CR44","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/jbmr.3421","volume":"33","author":"D Olvera","year":"2018","unstructured":"Olvera D, Stolzenfeld R, Marini JC, Caird MS, Kozloff KM (2018) Low dose of bisphosphonate enhances sclerostin antibody-induced trabecular bone mass gains in brtl\/+ osteogenesis imperfecta mouse model. J Bone Miner Res 33:1272\u20131282","journal-title":"J Bone Miner Res"},{"key":"2380_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bone.2019.04.011","volume":"124","author":"M Cardinal","year":"2019","unstructured":"Cardinal M, Tys J, Roels T, Lafont S, Ominsky MS, Devogelaer JP et al (2019) Sclerostin antibody reduces long bone fractures in the oim\/oim model of osteogenesis imperfecta. Bone 124:137\u2013147","journal-title":"Bone"},{"key":"2380_CR46","doi-asserted-by":"crossref","unstructured":"Lehmann J, Thiele S, Baschant U, Rachner TD, Niehrs C, Hofbauer LC et al (2021) Mice lacking dkk1 in t cells exhibit high bone mass and are protected from estrogen-deficiency-induced bone loss. iScience 24:102224.","DOI":"10.1016\/j.isci.2021.102224"},{"key":"2380_CR47","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/jbmr.4809","volume":"38","author":"MK Simic","year":"2023","unstructured":"Simic MK, Mohanty ST, Xiao Y, Cheng TL, Taylor VE, Charlat O et al (2023) Multi-targeting dkk1 and lrp6 prevents bone loss and improves fracture resistance in multiple myeloma. J Bone Miner Res 38:814\u2013828","journal-title":"J Bone Miner Res"},{"key":"2380_CR48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bone.2014.07.039","volume":"71","author":"H Jin","year":"2015","unstructured":"Jin H, Wang B, Li J, Xie W, Mao Q, Li S et al (2015) Anti-dkk1 antibody promotes bone fracture healing through activation of \u03b2-catenin signaling. Bone 71:63\u201375","journal-title":"Bone"},{"key":"2380_CR49","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bone.2019.01.021","volume":"121","author":"C Zhang","year":"2019","unstructured":"Zhang C, Zhao Z, Sun Y, Xu L, JiaJue R, Cui L et al (2019) Clinical and genetic analysis in a large chinese cohort of patients with x-linked hypophosphatemia. Bone 121:212\u2013220","journal-title":"Bone"},{"key":"2380_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2023.05.001","volume":"118","author":"SAP Chubb","year":"2023","unstructured":"Chubb SAP, Vasikaran SD, Gillett MJ (2023) Reference intervals for plasma \u03b2-ctx and p1np in children: A systematic review and pooled estimates. Clin Biochem 118:110582","journal-title":"Clin Biochem"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02380-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02380-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02380-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T21:04:46Z","timestamp":1728939886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02380-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["2380"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02380-9","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"23 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest. The authors have no disclosure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Scientific Ethics Committee of PUMCH.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consents were obtained from legal guardian of each OI patient and healthy children.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}